{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:14:26Z","timestamp":1793830466521,"version":"4.6.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.resinv.2024.03.007","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T13:15:31Z","timestamp":1712150131000},"page":"481-487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Risk factors for interstitial lung disease in patients with non-small cell lung cancer with epidermal growth factor receptor-tyrosine kinase inhibitors: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7087-1595","authenticated-orcid":false,"given":"Yosuke","family":"Fukuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7269-3956","authenticated-orcid":false,"given":"Yoshitaka","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6535-8279","authenticated-orcid":false,"given":"Koichi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Manabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Sagara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2024.03.007_bib1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR -Mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2024.03.007_bib2","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2024.03.007_bib3","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.resinv.2024.03.007_bib4","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non\u2013small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2024.03.007_bib5","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.resinv.2024.03.007_bib6","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.lungcan.2015.01.026","article-title":"Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer","volume":"88","author":"Takeda","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.resinv.2024.03.007_bib7","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s10147-021-02043-2","article-title":"Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B)","volume":"27","author":"Tsubata","year":"2022","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.resinv.2024.03.007_bib8","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.resinv.2024.03.007_bib9","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jclinepi.2012.09.016","article-title":"Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity","volume":"66","author":"Kim","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.resinv.2024.03.007_bib10","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1200\/JCO.2005.04.9866","article-title":"Predictive factors for interstitial lung disease, antitumor response, and survival in non\u2013small-cell lung cancer patients treated with gefitinib","volume":"24","author":"Ando","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2024.03.007_bib11","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4143\/crt.2014.201","article-title":"Gefitinib-induced interstitial lung disease in Korean lung cancer patients","volume":"48","author":"Beom","year":"2016","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.resinv.2024.03.007_bib12","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.jtho.2020.08.025","article-title":"Real-world evaluation of factors for interstitial lung disease incidence and radiologic characteristics in patients with EGFR T790M\u2013positive NSCLC treated with osimertinib in Japan","volume":"15","author":"Gemma","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2024.03.007_bib13","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00130404-200509000-00010","article-title":"Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama lung cancer study group","volume":"11","author":"Hotta","year":"2005","journal-title":"Cancer J"},{"key":"10.1016\/j.resinv.2024.03.007_bib14","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/JTO.0b013e3181ca12e0","article-title":"Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese patients with non-small cell lung cancer: the Okayama lung cancer study group experience","volume":"5","author":"Hotta","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2024.03.007_bib15","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.cllc.2014.06.003","article-title":"Association between baseline pulmonary status and interstitial lung disease in patients with non\u2013small-cell lung cancer treated with erlotinib\u2014a cohort study","volume":"15","author":"Johkoh","year":"2014","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.resinv.2024.03.007_bib16","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/COC.0b013e318162f13b","article-title":"Impact of preexisting pulmonary fibrosis detected on chest radiograph and CT on the development of gefitinib-related interstitial lung disease","volume":"31","author":"Naito","year":"2008","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.resinv.2024.03.007_bib17","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1097\/JTO.0b013e3182598abb","article-title":"Postmarketing surveillance study of erlotinib in Japanese patients with non\u2013small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR)","volume":"7","author":"Nakagawa","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2024.03.007_bib18","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.chest.2022.05.035","article-title":"Drug-related pneumonitis induced by osimertinib as first-line treatment for epidermal growth factor receptor mutation-positive non-small cell lung cancer","volume":"162","author":"Sato","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2024.03.007_bib19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.lungcan.2004.01.010","article-title":"Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib","volume":"45","author":"Takano","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1016\/j.resinv.2024.03.007_bib20","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2482\/haigan.62.292","article-title":"A study of the relationship between interstitial lung abnormalities and osimertinib-induced lung injury","volume":"62","author":"Sumii","year":"2022","journal-title":"Haigan"},{"key":"10.1016\/j.resinv.2024.03.007_bib21","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2024.03.007_bib22","first-page":"343","article-title":"Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis","volume":"11","author":"Meyer","year":"2017","journal-title":"Expet Rev Respir Med"},{"key":"10.1016\/j.resinv.2024.03.007_bib23","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12931-016-0454-0","article-title":"Predicting survival of patients with idiopathic pulmonary fibrosis using GAP score: a nationwide cohort study","volume":"17","author":"Lee","year":"2016","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2024.03.007_bib24","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1183\/09031936.00165207","article-title":"Sex differences in physiological progression of idiopathic pulmonary fibrosis","volume":"31","author":"Han","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2024.03.007_bib25","doi-asserted-by":"crossref","first-page":"L510","DOI":"10.1152\/ajplung.00122.2011","article-title":"Age and sex dimorphisms contribute to the severity of bleomycin-induced lung injury and fibrosis","volume":"301","author":"Redente","year":"2011","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.resinv.2024.03.007_bib26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1165\/rcmb.2007-0340OC","article-title":"Male sex hormones exacerbate lung function impairment after bleomycin-induced pulmonary fibrosis","volume":"39","author":"Voltz","year":"2008","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.resinv.2024.03.007_bib27","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1164\/ajrccm.155.1.9001319","article-title":"Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis","volume":"155","author":"Baumgartner","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2024.03.007_bib28","first-page":"259","article-title":"Occupational and environmental factors and idiopathic pulmonary fibrosis in Japan","volume":"49","author":"Miyake","year":"2005","journal-title":"Ann Occup Hyg"},{"key":"10.1016\/j.resinv.2024.03.007_bib29","article-title":"Factors associated with interstitial lung disease in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"18","author":"Zhang","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.resinv.2024.03.007_bib30","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1165\/rcmb.2005-0203OC","article-title":"Transforming growth factor-\u03b2 1 drives airway remodeling in cigarette smoke\u2013exposed tracheal explants","volume":"33","author":"Wang","year":"2005","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.resinv.2024.03.007_bib31","doi-asserted-by":"crossref","first-page":"550","DOI":"10.18632\/oncotarget.939","article-title":"Epidermal growth factor receptor tyrosine kinase inhibition up-regulates interleukin-6 in cancer cells and induces subsequent development of interstitial pneumonia","volume":"4","author":"Ishiguro","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.resinv.2024.03.007_bib32","doi-asserted-by":"crossref","first-page":"43605","DOI":"10.18632\/oncotarget.6186","article-title":"Metformin attenuates gefitinib-induced exacerbation of pulmonary fibrosis by inhibition of TGF-\u03b2 signaling pathway","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.resinv.2024.03.007_bib33","first-page":"2026","article-title":"Cigarette smoking impairs the response of EGFR-TKIs therapy in lung adenocarcinoma patients by promoting EGFR signaling and epithelial-mesenchymal transition","volume":"7","author":"Liu","year":"2015","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.resinv.2024.03.007_bib34","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/jjco\/hyt049","article-title":"Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405)","volume":"43","author":"Akamatsu","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.resinv.2024.03.007_bib35","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12931-023-02359-9","article-title":"Interstitial lung abnormalities in a large clinical lung cancer screening cohort: association with mortality and ILD diagnosis","volume":"24","author":"Patel","year":"2023","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2024.03.007_bib36","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.2169\/internalmedicine.4552-20","article-title":"Pembrolizumab for previously untreated patients with advanced non-small-cell lung cancer and preexisting interstitial lung disease","volume":"59","author":"Fujita","year":"2020","journal-title":"Intern Med"},{"key":"10.1016\/j.resinv.2024.03.007_bib37","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/1759-7714.13725","article-title":"Pre-existing interstitial lung disease does not affect prognosis in non-small cell lung cancer patients with PD-L1 expression \u226550% on first-line pembrolizumab","volume":"12","author":"Yamaguchi","year":"2021","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.resinv.2024.03.007_bib38","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.lungcan.2018.10.001","article-title":"Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: a retrospective analysis","volume":"125","author":"Yamaguchi","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.resinv.2024.03.007_bib39","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.21037\/tlcr-22-162","article-title":"Impact of treatment line on risks and benefits of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer and interstitial lung disease: a systematic review and meta-analysis of cohort studies","volume":"11","author":"Matsumoto","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.resinv.2024.03.007_bib40","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1165\/rcmb.2002-0262OC","article-title":"Inverse effects of interleukin-6 on apoptosis of fibroblasts from pulmonary fibrosis and normal lungs","volume":"29","author":"Moodley","year":"2003","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.resinv.2024.03.007_bib41","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1165\/rcmb.2007-0299OC","article-title":"Role of interleukin-6 in bleomycin-induced lung inflammatory changes in mice","volume":"38","author":"Saito","year":"2008","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.resinv.2024.03.007_bib42","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.lungcan.2018.06.032","article-title":"Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: meta-analysis of 153 cohorts with 15,713 patients: meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC","volume":"123","author":"Suh","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.resinv.2024.03.007_bib43","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.annonc.2021.11.010","article-title":"A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial","volume":"33","author":"Soo","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.resinv.2024.03.007_bib44","doi-asserted-by":"crossref","first-page":"841","DOI":"10.4143\/crt.2022.1438","article-title":"EGFR-TKI combined with pemetrexed versus EGFR-TKI monotherapy in advanced EGFR-mutated nsclc: a prospective, randomized, exploratory study","volume":"55","author":"Gu","year":"2023","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.resinv.2024.03.007_bib45","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1016\/j.cllc.2020.06.005","article-title":"EGFR tyrosine kinase inhibitor (TKI) combined with concurrent or sequential chemotherapy for patients with advanced lung cancer and gradual progression after first-line EGFR-TKI therapy: a randomized controlled study","volume":"22","author":"Chang","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.resinv.2024.03.007_bib46","doi-asserted-by":"crossref","DOI":"10.1177\/2050312120918264","article-title":"Analysis of drug-induced interstitial lung disease using the Japanese Adverse Drug Event Report database","volume":"8","author":"Matsumoto","year":"2020","journal-title":"SAGE Open Med"},{"key":"10.1016\/j.resinv.2024.03.007_bib47","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1001\/jamaoncol.2017.4526","article-title":"EGFR-TKI-Associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer","volume":"4","author":"Oshima","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.resinv.2024.03.007_bib48","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/annonc\/mdw647","article-title":"High incidence of interstitial lung disease following practical use of osimertinib in patients who had undergone immediate prior nivolumab therapy","volume":"28","author":"Kotake","year":"2017","journal-title":"Ann Oncol"}],"updated-by":[{"DOI":"10.1016\/j.resinv.2025.02.006","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000}}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534524000492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534524000492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T09:39:28Z","timestamp":1713346768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534524000492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2212534524000492"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2024.03.007","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.resinv.2025.02.006","asserted-by":"object"}]},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors for interstitial lung disease in patients with non-small cell lung cancer with epidermal growth factor receptor-tyrosine kinase inhibitors: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2024.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}